Myopia
Conditions
Brief summary
Atropine eye drops are increasingly prescribed for the management of progressive myopia or short-sightedness. A previous study suggested that the back of the eye or choroid may be a part of the mechanism by which it induces its effects. The aim of this study is to characterize the effects of atropine on choroidal thickness and the influence of time of administration (am vs pm). It is hypothesized that the atropine's effect on choroidal thickness will vary with baseline thickness related to diurnal rhythm, where thicker baseline thickness will show a reduced choroidal response.
Detailed description
Atropine eye drops are increasingly prescribed for the management of progressive myopia or short-sightedness. A previous study suggested that the back of the eye or choroid may be a part of the mechanism by which it induces its effects. The choroid shows diurnal variation and the efficacy of atropine on myopia control in relationship to the patient's baseline choroidal thickness is unknown. Thus, the objective of this study is to provide data to characterize the influence of atropine on choroid thickness. The study aims are to: 1. Determine the effect of am or pm atropine application on choroid thickness 2. Determine the effect of atropine on choroid thickness in relationship to baseline thickness Participants will be asked to attend a screening session and 13 study visits. Following the screening visit, participants will be scheduled to return for 4 visits across 12 hours (4 hour intervals starting from 8am) in a single day where eye shape measurements will be taken to characterize diurnal variations in eye shape. Subjects will then be randomized to receive a drop of 1% atropine eye drops in both eyes in the morning or a night. Measurements of the shape of the front and back of the eye will be taken after approximately 1, 12, 24 and 96 hours after drop instillation. After a 2 week washout period, 1% atropine eye drops will be administered either in the morning or at night (the visit that was not previously scheduled) and measurements of the shape of the front and back of the eye will be taken after approximately 1, 12, 24 and 96 hours after drop instillation.
Interventions
DRUGAtropine Sulfate 1% Oph Soln
Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
Sponsors
The University of New South Wales
State University of New York College of Optometry
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Good general and ocular health * Soft contact lens wearers to cease lens wear for at least 24 hours * No previous rigid gas permeable lens wear
Exclusion criteria
* History of ocular surgery, including refractive surgery * Amblyopia * Use of ocular medications * Known allergies or sensitivity to atropine * Pregnant, plan to become pregnant, or are breastfeeding * Taking monoamine oxidase inhibitors (MAOIs)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Choroidal thickness | Baseline, then after approximately 1, 12, 24 and 96 hours after atropine instillation | Change in choroidal thickness after atropine |
Countries
United States
Outcome results
None listed